CalciMedica, Inc.
CALC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001534133
No open-market purchases or sales by CalciMedica, Inc. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $8.39M in total; no superinvestor holds it.
13F holders, Q3 2022
Institutional positions in CalciMedica, Inc. as of Sep 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 25
- 0 vs. Q2 2022
- Shares held
- 10.8M
- +84.2K (+0.8%) vs. Q2 2022
- Total value
- $10.2M
- −$1.53M (−13.0%) vs. Q2 2022
- New holders
- 3
- 6 more added
- Sold out
- 3
- 3 more reduced
Compare with Q2 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CALC on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 31 | $8.39M |
| Q1 2026 | 27 | $592.5K |
| Q4 2025 | 31 | $24.2M |
| Q3 2025 | 31 | $10.9M |
| Q2 2025 | 30 | $5.93M |
| Q1 2025 | 30 | $7.49M |
| Q4 2024 | 29 | $15.1M |
| Q3 2024 | 24 | $13.6M |
| Q2 2024 | 21 | $11.8M |
| Q1 2024 | 20 | $14.8M |
| Q4 2023 | 12 | $1.49M |
| Q3 2023 | 13 | $1.56M |
| Q2 2023 | 13 | $2.72M |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 27 | $5.97M |
| Q3 2022 | 25 | $10.2M |
| Q2 2022 | 25 | $11.7M |
| Q1 2022 | 27 | $13.5M |
| Q4 2021 | 28 | $20.7M |
| Q3 2021 | 27 | $37.0M |
| Q2 2021 | 41 | $63.7M |
| Q1 2021 | 51 | $72.8M |
Institutions, Q3 2022
Shares, value and share of portfolio for each institution holding CalciMedica, Inc.; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| UBS Group AG | 209 | $0 | 0.00% | −15,785−98.7% | Reduced |
| Wells Fargo & Company | 104 | $0 | 0.00% | +15+16.9% | Added |
| Simplex Trading, LLC | 966 | $0 | 0.00% | +750+347.2% | Added |
| Cutler Group LP | 200 | $0 | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 7 | $0 | 0.00% | +7 | New |
| BNP Paribas Arbitrage, SA | 114 | $107 | 0.00% | +114 | New |
| BlackRock Inc. | 642 | $1.00K | 0.00% | 00.0% | Unchanged |
| Federated Hermes, Inc. | 2,379 | $2.00K | 0.00% | 00.0% | Unchanged |
| The PNC Financial Services Group, Inc. | 8,612 | $8.00K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 12,011 | $11.0K | 0.00% | +3,001+33.3% | Added |
| Jane Street Group, LLC | 11,455 | $11.0K | 0.00% | +11,455 | New |
| Northern Trust Corp | 16,104 | $15.0K | 0.00% | 00.0% | Unchanged |
| Brown Advisory Inc | 18,333 | $17.0K | 0.00% | +1,233+7.2% | Added |
| Advisor Group Holdings, Inc. | 19,000 | $18.0K | 0.00% | 00.0% | Unchanged |
| State Street Corp | 35,073 | $33.0K | 0.00% | 00.0% | Unchanged |
| Johnson & Johnson | 49,547 | $47.0K | 0.01% | 00.0% | Unchanged |
| Susquehanna International Group, LLP | 63,241 | $59.0K | 0.00% | +52,012+463.2% | Added |
| Bridgeway Capital Management, LLC | 64,000 | $60.0K | 0.00% | −50,000−43.9% | Reduced |
| Geode Capital Management, LLC | 66,393 | $62.0K | 0.00% | 00.0% | Unchanged |
| Bank of New York Mellon Corp | 100,981 | $95.0K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 200,492 | $189.0K | 0.00% | +148,392+284.8% | Added |
| First Manhattan Co | 292,003 | $274.0K | 0.00% | 00.0% | Unchanged |
| Vanguard Group Inc | 419,744 | $394.0K | 0.00% | −33,940−7.5% | Reduced |
| OrbiMed Advisors LLC | 4,163,347 | $3.92M | 0.08% | 00.0% | Unchanged |
| Deerfield Management Company, L.P. (Series C) | 5,281,713 | $4.97M | 0.10% | 00.0% | Unchanged |
| Two Sigma Investments, LP | 0 | $0 | 0.00% | −17,218−100.0% | Sold out |
| Levin Capital Strategies, L.P. | 0 | $0 | 0.00% | −15,000−100.0% | Sold out |
| FMR LLC | 0 | $0 | 0.00% | −800−100.0% | Sold out |